BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

HistoIndex partners with A*STAR to advance early-stage development of pipeline therapies for fibrotic diseases in Singapore

October 19, 2026 | News

HistoIndex's platform will support the rigorous evaluation of A*STAR's pipeline of therapeutic candidates



HistoIndex, a pioneer in AI-driven digital pathology for fibrotic diseases, and the Agency for Science, Technology and Research (A*STAR), Singapore's lead public sector R&D agency, have signed a Memorandum of Understanding (MoU) to collaborate on the preclinical evaluation and characterisation of therapeutic candidates for various fibrotic diseases, including cancer-associated fibrosis.

The partnership will bring together A*STAR's scientific expertise and therapeutic development capabilities with HistoIndex's proprietary imaging technology and AI-powered fully quantitative tissue analysis.

By providing objective, sensitive and accurate measures of fibrosis and treatment response, HistoIndex's platform will support the rigorous evaluation of A*STAR's pipeline of therapeutic candidates and help researchers make more informed decisions on which candidates to advance.

Beyond the evaluation of therapeutic candidates, the collaboration will also provide a platform for scientific exchange between A*STAR and HistoIndex, with opportunities to explore areas such as biomarker discovery, translational research, joint therapeutic development and commercialisation.

"Fibrotic diseases, including cancer-associated fibrosis, remain challenging to evaluate during early-development. Understanding whether a therapeutic candidate can prevent, halt or reverse fibrosis requires accurate and objective measurement of changes in fibrotic tissue. This collaboration will help us assess these effects more rigorously and make better-informed development decisions, ultimately helping to advance innovations that improve patient outcomes," said Dr Lisa Ooi, Assistant Chief Executive of A*STAR's Biomedical Research Council (BMRC).